Evidence map›Paper›PMID 41410504›Full record

ReviewAmerican journal of medical genetics. Part A2026

Genetic and Phenotypic Features of the Five Known Polyaminopathies: A Critical Narrative Review.

Elizabeth A VanSickle, Sara M Sarasua, Tracy Lowe, Christopher L Farrell, Luigi Boccuto, Charles Schwartz, Anthony E Pegg, Angela Peron, Victor Faundes, Mythily Ganapathi and 17 more

Abstract readReview
In one paragraph

Review in American journal of medical genetics. Part A, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Elizabeth A VanSickleSchool of Nursing, Healthcare Genetics and Genomics Program, Clemson University, Clemson, South Carolina, USA.ORCID 0000-0001-5504-9248
Sara M SarasuaSchool of Nursing, Healthcare Genetics and Genomics Program, Clemson University, Clemson, South Carolina, USA.
Tracy LoweSchool of Nursing, Healthcare Genetics and Genomics Program, Clemson University, Clemson, South Carolina, USA.ORCID 0000-0003-1115-1405
Christopher L FarrellSchool of Nursing, Healthcare Genetics and Genomics Program, Clemson University, Clemson, South Carolina, USA.
Luigi BoccutoSchool of Nursing, Healthcare Genetics and Genomics Program, Clemson University, Clemson, South Carolina, USA.
Charles SchwartzInternational Center for Polyamine Disorders, Grand Rapids, Michigan, USA.ORCID 0000-0002-7770-1943
Anthony E PeggInternational Center for Polyamine Disorders, Grand Rapids, Michigan, USA.
Angela PeronInternational Center for Polyamine Disorders, Grand Rapids, Michigan, USA.ORCID 0000-0002-1769-6548
Victor FaundesLaboratorio de Genética y Enfermedades Metabólicas, Instituto de Nutrición y Tecnología de los Alimentos, Universidad de Chile, Santiago, Chile.
Mythily GanapathiDepartment of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
Wendy K ChungDepartment of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Alban ZieglerDepartment of Medical Genetics, University Hospital of Toulouse, Toulouse, France.
Floris HofstedeUniversity Medical Center Utrecht, Utrecht, the Netherlands.
Clément ProuteauDepartment of Genetics, University Hospital of Angers, Angers, France.
Katharina SteindlInstitute of Medical Genetics, University of Zurich, Zurich, Switzerland.
Colleen OlsonDHPS Foundation, Reston, Virginia, USA.
Orrin DevinskyDHPS Foundation, Reston, Virginia, USA.
Teresa L MastracciDepartment of Biology, Indiana University-Indianapolis, Indianapolis, Indiana, USA.
Robert A CaseroThe Johns Hopkins University, Baltimore, Maryland, USA.
Tracy Murray StewartThe Johns Hopkins University, Baltimore, Maryland, USA.
Susan GilmourInternational Center for Polyamine Disorders, Grand Rapids, Michigan, USA.ORCID 0000-0001-6228-860X
Teri KoernerThe Snyder-Robinson Foundation, McLean, Virginia, USA.
Mary Jo KutlerThe Snyder-Robinson Foundation, McLean, Virginia, USA.
Surender RajasekaranInternational Center for Polyamine Disorders, Grand Rapids, Michigan, USA.
Julianne MichaelDivision of Medical Genetics, Corewell Health/Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA.
André S BachmannInternational Center for Polyamine Disorders, Grand Rapids, Michigan, USA.
Caleb P BuppDivision of Medical Genetics, Corewell Health/Helen DeVos Children's Hospital, Grand Rapids, Michigan, USA.

Funding

Leveraging modulation of polyamine metabolism for therapeutic advantage in genetic disordersR01HD110500 · NICHD · MICHIGAN STATE UNIVERSITY · PI ANDRE S BACHMANN, Caleb Bupp · 2023 to 2026
$2.7M
Exocrine-Endocrine Crosstalk and Determinants of Beta Cell GrowthR01DK121987 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI MASTRACCI, TERESA LOUISE · 2020 to 2024
$2.0M
NICHD NIH HHS R01 HD110500NIDDK NIH HHS R01 DK121987
6 · The paper itself

Abstract

Polyaminopathies are a recently described family of rare genetic neurodevelopmental disorders. Polyaminopathies disrupt the biosynthesis of the primary polyamines: putrescine, spermidine, and spermine. Snyder-Robinson syndrome results from hemizygous loss-of-function variants in the spermine synthase (SMS) gene, resulting in decreased or complete loss of spermine synthase enzyme activity. Bachmann-Bupp syndrome results from heterozygous gain-of-function variants in the ornithine decarboxylase 1 (ODC1) gene, resulting in increased ornithine decarboxylase enzyme activity. Faundes-Banka syndrome results from heterozygous loss-of-function variants in the eukaryotic translation initiation factor 5A (EIF5A) gene, impairing eIF5A protein function. DHPS (deoxyhypusine synthase) deficiency is an autosomal recessive disease and results from bi-allelic hypomorphic variants in the deoxyhypusine synthase (DHPS) gene, which results in reduced deoxyhypusine synthase enzyme activity. Finally, DOHH (deoxyhypusine hydroxylase) disorder is an autosomal recessive disorder caused by bi-allelic loss-of-function variants in the deoxyhypusine hydroxylase (DOHH) gene, which causes decreased deoxyhypusine hydroxylase enzyme activity. Snyder-Robinson syndrome was first described in 1969, while the other four syndromes have only been identified in the past 7 years. A comprehensive phenotypic and genotypic description of these five syndromes is needed. We review the clinical and genetic features of these five polyaminopathies to create an inclusive clinical resource. A systematic keyword search strategy was used to identify all published cases in PubMed, Web of Science, and Scopus databases. The five known syndromes associated with the polyamine pathway share many similar clinical phenotypes, and yet patients with each syndrome present with distinctive syndromic features. This review will serve as a valuable resource for clinicians diagnosing and caring for patients with these rare polyaminopathies.

Indexed as

Neurodevelopmental DisordersEukaryotic Translation Initiation Factor 5AHumansOxidoreductases Acting on CH-NH Group DonorsPeptide Initiation FactorsPhenotypePolyaminesRNA-Binding ProteinsSpermine SynthaseX-Linked Intellectual Disabilitydeoxyhypusine synthaseEukaryotic Translation Initiation Factor 5AOxidoreductases Acting on CH-NH Group DonorsPeptide Initiation FactorsPolyaminesRNA-Binding ProteinsSpermine SynthaseBachmann–Bupp syndromedeoxyhypusine hydroxylase disorderdeoxyhypusine synthase deficiencyDHPSDOHHEIF5AFaundes‐Banka syndromeODC1SMSSnyder–Robinson syndrome

Identifiers

PMID41410504
PMCPMC13270430

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.